Clinical and regulatory intelligence for Pulmonary Fibrosis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

Boehringer →

Salvia →

Relevant companies

Boehringer Ingelheim →

Recent signals(2)

ClinicalJuly 24, 2026

Salvia miltiorrhiza shows promise in treating pulmonary fibrosis through fibroblast mitophagy

Salvia miltiorrhiza Bunge has demonstrated potential anti-fibrotic effects in pulmonary fibrosis through promoting fibroblast mitophagy.

ClinicalJune 26, 2026

Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients

A follow-up study is underway to evaluate the long-term tolerance and efficacy of nerandomilast in patients with pulmonary fibrosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Herbal Medicine →

Pulmonary Fibrosis →

Pulmonology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.